Publications by authors named "I A Caspers"
Background: Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC) and diffuse (dif-GC) gastric cancer.
Methods: Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts.
Background: Lynch syndrome increases the risk of gastric cancer (GC) and duodenal cancer (DC), particularly in individuals with and pathogenic variants (PVs). To provide further insight into whether, and from what age, esophagogastroduodenoscopy (EGD) surveillance may be beneficial, we evaluated the cumulative incidence and tumour characteristics of GC and DC in a large nationwide cohort of Dutch individuals with LS.
Methods: For this retrospective nationwide cohort study, clinical data of individuals with LS registered at the Dutch Hereditary Cancer Registry were matched with pathology reports filed by the Dutch Pathology registry.
Article Synopsis
- The study examines how sex affects outcomes in patients with resectable gastric cancer, focusing on histological subtype differences.
- It analyzes data from the CRITICS-trial, comparing survival rates, toxicity, and compliance between male and female patients.
- Results show that females have higher rates of positive tumor margins in diffuse gastric cancer and experience more treatment-related toxicity, but this does not significantly impact their treatment effectiveness.
Background: In the era of individualized gastric cancer (GC) treatment, accurate determination of histological subtype becomes increasingly relevant. As yet, it is unclear whether preoperative chemotherapy may affect the histological subtype. The aim of this study was to assess concordance in histological subtype between pretreatment biopsies and surgical resection specimens before and after the introduction of perioperative treatment.
View Article and Find Full Text PDFArticle Synopsis
- Perioperative chemotherapy is the standard treatment for resectable gastric cancer, with oxaliplatin gaining preference over cisplatin, though evidence for its superiority is lacking.
- The CRITICS trial compared outcomes between patients using cisplatin (632) and oxaliplatin (149) and examined their effects on patient health and tumor response.
- While both drugs led to severe toxicity rates (67% for cisplatin vs. 60% for oxaliplatin), the overall survival and tumor response outcomes showed no significant differences, indicating both are viable treatment options.